E
Evangelos Terpos
Researcher at National and Kapodistrian University of Athens
Publications - 858
Citations - 33515
Evangelos Terpos is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 73, co-authored 725 publications receiving 25857 citations. Previous affiliations of Evangelos Terpos include Hammersmith Hospital & Imperial College London.
Papers
More filters
Journal ArticleDOI
Serum levels of total-RANKL in multiple myeloma.
Christian Jakob,Andrea Goerke,Evangelos Terpos,Jan Sterz,Ulrike Heider,Dagmar Kühnhardt,Susanne Ziefle,Lorenz Kleeberg,Maren Mieth,Ivana von Metzler,Christian Müller,Orhan Sezer +11 more
TL;DR: This study demonstrates for the first time that serum tRANKL reflects advanced disease, lytic bone destruction, and poor prognosis in MM.
Journal ArticleDOI
Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia : Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase
Efstathios Kastritis,Konstantinos Zervas,Panagiotis Repoussis,Evridiki Michali,Eirini Katodrytou,Athanasios Zomas,Argiris Simeonidis,Evangelos Terpos,Sossana Delimbassi,Amalia Vassou,Dimitra Gika,Meletios A. Dimopoulos +11 more
TL;DR: The addition of elevated serum lactate dehydrogenase in the IPSS improved the ability of IPSS to identify a group of patients with a significantly worse outcome (median survival, 55 months) and could discriminate 3 risk groups with significantly different OS or DSS.
Journal Article
Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria.
John Meletis,Evangelos Terpos +1 more
TL;DR: This review focuses on the presence of PNH clones in other hematological disorders, including aplastic anemia (AA), myelodysplastic syndromes (MDS), acute leukemias, and myeloproliferative and lymphopromes.
Journal ArticleDOI
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
TL;DR: In this article, the authors provide an overview of the multifaceted role of the bone marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma.
Journal ArticleDOI
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
TL;DR: Bisphosphonates can inhibit osteoclast-mediated osteolysis, thereby reducing the risk of SREs, ameliorating bone pain, and potentially prolonging survival in patients with MM.